Humana AB (“Humana” or the “Company”), a leading Nordic care provider, has announced the outcome of the offering of new issued shares and sale of existing shares in the Company (the “Offering”) and listing on Nasdaq Stockholm. The Offering attracted strong interest both among Swedish and international institutional investors. The Offering was substantially over-subscribed.
- The final price in the Offering has been set at SEK 62 per share, corresponding to a market capitalisation of Humana of approximately SEK 3.3 billion
- The Offering comprises in total 12,622,721 shares, of which 7,258,064 are newly issued shares offered by the Company and 5,364,657 are shares offered by the selling shareholders
- The newly issued shares will provide the Company with gross proceeds of approximately SEK 450 million before deduction of costs related to the Offering
- Given full exercise of the Over-Allotment Option, the Offering will comprise 14,305,750 shares, corresponding to a total value of the Offering of approximately 887 SEK million and 26.9 per cent of the total number of shares outstanding in the Company after completion of the Offering
- The total number of shares in the Company comprises 53,140,064 shares after the Offering
- Argan Capital will hold 55.7 per cent of the total number of shares outstanding in the Company after completion of the Offering
- Of the approximately 20,000 persons that have applied for shares in the Offering to the general public, all have been allotted shares
- Trading in the Company’s shares on Nasdaq Stockholm commences today, 22 March 2016, under the trading symbol “HUM”
- Settlement takes place on 24 March 2016
Carnegie acted as Joint Global Co-ordinator and Joint Bookrunner